Elevation Oncology reports Q4 EPS (18c), consensus (22c)

As of December 31, 2024, Elevation Oncology (ELEV) had cash, cash equivalents and marketable securities totaling $93.2M vs. $83.1M as of December 31, 2023. “We continue to advance our Claudin 18.2 ADC program, EO-3021, for the treatment of advanced gastric/GEJ cancer in the earlier lines settings,” said CEO Joseph Ferra. “Based on the competitive anti-tumor activity and differentiated safety profile observed to date, we believe EO-3021 has the potential to benefit a broad patient population. Currently, we are evaluating EO-3021 in combinations with approved therapies in the first- and second-line settings, where we have a first-mover advantage and the opportunity to address significant markets, while also progressing our monotherapy cohort toward an additional data readout in Q2…We believe both EO-3021 and EO-1022 have the potential to elevate cancer care and are eager to share updates on both programs as we move through 2025.”